$104.02
1.691.65%
At Close: -
$104.00
-0.02-0.02%
After Hours: 4:53 PM EDT
15 minutes delayed
Abbott Laboratories
ABTNYSE
want to know what
the Bulls & Bears Say?
Abbott Laboratories (NYSE:ABT) 주식, 분석가 평가, 목표 가격, 예측
Abbott Laboratories has a consensus price target of $123.32 based on the ratings of 100 analysis. The 3 most-recent analyst ratings were released by Evercore ISI Group, RBC Capital, and Goldman Sachs on July 2, 2024, June 4, 2024, and May 30, 2024, respectively. With an average price target of $122 between Evercore ISI Group, RBC Capital, and Goldman Sachs, there's an implied 17.31% upside for Abbott Laboratories from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
RBC Capital
Goldman Sachs
Citigroup
Barclays
1calculated from analyst ratings
Analyst Ratings for Abbott Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | Buy Now | 15.38% | Evercore ISI Group | Vijay Kumar | $125 → $120 | Maintains | Outperform | Get Alert |
| 06/04/2024 | Buy Now | 20.19% | RBC Capital | Shagun Singh | $125 → $125 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2024 | Buy Now | 16.35% | Goldman Sachs | David Roman | → $121 | Initiates | → Buy | Get Alert |
| 05/22/2024 | Buy Now | 14.42% | Citigroup | Joanna Wiensch | $128 → $119 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 34.62% | Barclays | Matt Miksic | $141 → $140 | Maintains | Overweight | Get Alert |
| 04/18/2024 | Buy Now | 20.19% | RBC Capital | Shagun Singh | $128 → $125 | Maintains | Outperform | Get Alert |
| 04/04/2024 | Buy Now | 20.19% | Evercore ISI Group | Vijay Kumar | $120 → $125 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | 23.08% | Citigroup | Joanne Wuensch | $126 → $128 | Maintains | Buy | Get Alert |
| 02/14/2024 | Buy Now | 23.08% | RBC Capital | Shagun Singh | → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/26/2024 | Buy Now | 35.58% | Barclays | Matt Miksic | $133 → $141 | Maintains | Overweight | Get Alert |
| 01/25/2024 | Buy Now | 21.15% | Citigroup | Joanne Wuensch | $123 → $126 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | 23.08% | RBC Capital | Shagun Singh | → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/25/2024 | Buy Now | 22.12% | Raymond James | Jayson Bedford | $124 → $127 | Maintains | Outperform | Get Alert |
| 01/11/2024 | Buy Now | 23.08% | RBC Capital | Shagun Singh | $119 → $128 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 19.23% | Raymond James | Jayson Bedford | $110 → $124 | Maintains | Outperform | Get Alert |
| 12/13/2023 | Buy Now | 16.35% | Wells Fargo | Lawrence Biegelsen | $116 → $121 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 2.88% | Morgan Stanley | David Lewis | $112 → $107 | Maintains | Equal-Weight | Get Alert |
| 10/19/2023 | Buy Now | 11.54% | Wells Fargo | Lawrence Biegelsen | $136 → $116 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | 5.77% | Raymond James | Jayson Bedford | $123 → $110 | Maintains | Outperform | Get Alert |
| 07/24/2023 | Buy Now | 26.92% | Barclays | Matt Miksic | $127 → $132 | Maintains | Overweight | Get Alert |
| 07/21/2023 | Buy Now | 7.69% | Morgan Stanley | David Lewis | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/21/2023 | Buy Now | 10.58% | Mizuho | Anthony Petrone | $110 → $115 | Assumes | Neutral → Neutral | Get Alert |
| 07/21/2023 | Buy Now | — | Wolfe Research | Mike Polark | — | Upgrade | Underperform → Peer Perform | Get Alert |
| 04/20/2023 | Buy Now | 25% | UBS | Matthew Korn | $117 → $130 | Maintains | Buy | Get Alert |
| 04/20/2023 | Buy Now | 18.27% | Raymond James | Jayson Bedford | $116 → $123 | Maintains | Outperform | Get Alert |
| 04/20/2023 | Buy Now | 22.12% | Barclays | Matt Miksic | $125 → $127 | Maintains | Overweight | Get Alert |
| 04/20/2023 | Buy Now | 25% | Citigroup | Joanne Wuensch | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 25% | BTIG | Ryan Zimmerman | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 11.54% | Raymond James | Jayson Bedford | $123 → $116 | Maintains | Outperform | Get Alert |
| 04/10/2023 | Buy Now | 30.77% | Wells Fargo | Lawrence Biegelsen | $140 → $136 | Maintains | Overweight | Get Alert |
| 04/05/2023 | Buy Now | 30.77% | Wells Fargo | Larry Biegelsen | $140 → $136 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | 12.5% | UBS | Danielle Antalffy | → $117 | Assumes | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 20.19% | Barclays | Matt Miksic | $122 → $125 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | 20.19% | BTIG | Marie Thibault | $120 → $125 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | 20.19% | Stifel | Rick Wise | $110 → $125 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | 18.27% | Raymond James | Jayson Bedford | $109 → $123 | Maintains | Outperform | Get Alert |
| 01/26/2023 | Buy Now | 26.92% | Bernstein | Lee Hambright | $125 → $132 | Maintains | Outperform | Get Alert |
| 01/25/2023 | Buy Now | 2.88% | Wolfe Research | Mike Polark | $92 → $107 | Maintains | Underperform | Get Alert |
| 01/24/2023 | Buy Now | 5.77% | Mizuho | Anthony Petrone | $105 → $110 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 27.88% | Morgan Stanley | Cecilia Furlong | $117 → $133 | Maintains | Overweight | Get Alert |
| 01/04/2023 | Buy Now | 17.31% | Barclays | Matt Miksic | $114 → $122 | Maintains | Overweight | Get Alert |
| 12/13/2022 | Buy Now | 25% | TD Cowen | Joshua Jennings | → $130 | Maintains | Outperform | Get Alert |
| 12/12/2022 | Buy Now | 20.19% | Citigroup | Joanne Wuensch | $114 → $125 | Maintains | Buy | Get Alert |
| 10/26/2022 | Buy Now | 0.96% | Mizuho | Anthony Petrone | → $105 | Initiates | → Neutral | Get Alert |
| 10/21/2022 | Buy Now | 9.62% | Barclays | Matt Miksic | $118 → $114 | Maintains | Overweight | Get Alert |
| 10/21/2022 | Buy Now | 4.81% | Raymond James | Jayson Bedford | $117 → $109 | Maintains | Outperform | Get Alert |
| 10/20/2022 | Buy Now | 9.62% | Citigroup | Joanna Wiensch | $117 → $114 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 15.38% | BTIG | Marie Thibault | $123 → $120 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 5.77% | Stifel | Rick Wise | $126 → $110 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 13.46% | JP Morgan | Robbie Marcus | $125 → $118 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | 12.5% | Morgan Stanley | Cecilia Furlong | $126 → $117 | Maintains | Overweight | Get Alert |
| 10/20/2022 | Buy Now | 21.15% | RBC Capital | Shagun Singh | $132 → $126 | Maintains | Outperform | Get Alert |
| 10/19/2022 | Buy Now | 5.77% | Evercore ISI Group | Vijay Kumar | $114 → $110 | Maintains | Outperform | Get Alert |
| 10/18/2022 | Buy Now | 13.46% | Barclays | Matt Miksic | → $118 | Initiates | → Overweight | Get Alert |
| 10/17/2022 | Buy Now | 18.27% | BTIG | Ryan Zimmerman | $126 → $123 | Maintains | Buy | Get Alert |
| 10/12/2022 | Buy Now | 5.77% | Jefferies | Matthew Taylor | → $110 | Initiates | → Hold | Get Alert |
| 10/11/2022 | Buy Now | 21.15% | Morgan Stanley | Cecilia Furlong | $132 → $126 | Maintains | Overweight | Get Alert |
| 10/10/2022 | Buy Now | 34.62% | Wells Fargo | Larry Biegelsen | $150 → $140 | Maintains | Overweight | Get Alert |
| 10/09/2022 | Buy Now | 44.23% | Wells Fargo | Larry Biegelsen | → $150 | Maintains | Overweight | Get Alert |
| 10/05/2022 | Buy Now | 12.5% | Citigroup | Joanna Wiensch | $123 → $117 | Maintains | Buy | Get Alert |
| 08/19/2022 | Buy Now | 34.62% | BTIG | Marie Thibault | → $140 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 44.23% | Wells Fargo | Larry Biegelsen | $155 → $150 | Maintains | Overweight | Get Alert |
| 07/28/2022 | Buy Now | 29.81% | Argus Research | David Toung | $150 → $135 | Maintains | Buy | Get Alert |
| 07/27/2022 | Buy Now | 23.08% | UBS | John Sourbeer | $142 → $128 | Maintains | Buy | Get Alert |
| 07/25/2022 | Buy Now | — | Goldman Sachs | Amit Hazan | $111 → $104 | Maintains | Sell | Get Alert |
| 07/22/2022 | Buy Now | 20.19% | JP Morgan | Robbie Marcus | → $125 | Maintains | Overweight | Get Alert |
| 07/21/2022 | Buy Now | 26.92% | RBC Capital | Shagun Singh | $143 → $132 | Maintains | Outperform | Get Alert |
| 07/21/2022 | Buy Now | 18.27% | Citigroup | Joanne Wuensch | $125 → $123 | Maintains | Buy | Get Alert |
| 07/21/2022 | Buy Now | 26.92% | Morgan Stanley | Cecilia Furlong | $134 → $132 | Maintains | Overweight | Get Alert |
| 07/20/2022 | Buy Now | 7.69% | Evercore ISI Group | Vijay Kumar | $116 → $112 | Maintains | Outperform | Get Alert |
| 07/18/2022 | Buy Now | 21.15% | BTIG | Ryan Zimmerman | $130 → $126 | Maintains | Buy | Get Alert |
| 07/18/2022 | Buy Now | 21.15% | Stifel | Rick Wise | — | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 28.85% | Morgan Stanley | Cecilia Furlong | $145 → $134 | Maintains | Overweight | Get Alert |
| 07/15/2022 | Buy Now | 12.5% | Raymond James | Jayson Bedford | $135 → $117 | Maintains | Outperform | Get Alert |
| 07/13/2022 | Buy Now | 25% | TD Cowen | Joshua Jennings | $150 → $130 | Maintains | Outperform | Get Alert |
| 07/06/2022 | Buy Now | — | Wolfe Research | Mike Polark | — | Initiates | → Underperform | Get Alert |
| 07/05/2022 | Buy Now | 11.54% | Evercore ISI Group | Vijay Kumar | $135 → $116 | Maintains | Outperform | Get Alert |
| 06/24/2022 | Buy Now | 25% | BTIG | Marie Thibault | $140 → $130 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | 39.42% | Morgan Stanley | Cecilia Furlong | $151 → $145 | Maintains | Overweight | Get Alert |
| 05/31/2022 | Buy Now | 34.62% | B of A Securities | Travis Steed | → $140 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 20.19% | Citigroup | Joanne Wuensch | $154 → $125 | Maintains | Buy | Get Alert |
| 04/21/2022 | Buy Now | 34.62% | SVB Leerink | Danielle Antalffy | → $140 | Maintains | Market Perform | Get Alert |
| 04/21/2022 | Buy Now | 29.81% | Raymond James | Jayson Bedford | $143 → $135 | Maintains | Outperform | Get Alert |
| 04/21/2022 | Buy Now | 37.5% | RBC Capital | Shagun Singh | $146 → $143 | Maintains | Outperform | Get Alert |
| 04/20/2022 | Buy Now | 36.54% | CFRA | — | $140 → $142 | Maintains | Buy | Get Alert |
| 04/10/2022 | Buy Now | 9.62% | Evercore ISI Group | Vijay Kumar | → $114 | Maintains | Outperform | Get Alert |
| 04/08/2022 | Buy Now | 44.23% | Wells Fargo | Larry Biegelsen | $155 → $150 | Maintains | Overweight | Get Alert |
| 03/02/2022 | Buy Now | 34.62% | B of A Securities | Travis Steed | → $140 | Reinstates | → Buy | Get Alert |
| 02/22/2022 | Buy Now | 49.04% | Wells Fargo | Larry Biegelsen | → $155 | Maintains | Overweight | Get Alert |
| 01/27/2022 | Buy Now | 33.65% | Credit Suisse | Matt Miksic | $138 → $139 | Maintains | Outperform | Get Alert |
| 01/27/2022 | Buy Now | 36.54% | UBS | Matthew Taylor | $138 → $142 | Maintains | Buy | Get Alert |
| 01/27/2022 | Buy Now | 45.19% | Morgan Stanley | Cecilia Furlong | $157 → $151 | Maintains | Overweight | Get Alert |
| 01/27/2022 | Buy Now | 37.5% | Raymond James | Jayson Bedford | $150 → $143 | Maintains | Outperform | Get Alert |
| 01/22/2022 | Buy Now | 20.19% | JP Morgan | Robbie Marcus | → $125 | Maintains | Overweight | Get Alert |
| 01/07/2022 | Buy Now | 50.96% | Morgan Stanley | Cecilia Furlong | $146 → $157 | Maintains | Overweight | Get Alert |
| 12/22/2021 | Buy Now | 44.23% | Raymond James | Jayson Bedford | $134 → $150 | Maintains | Outperform | Get Alert |
| 12/15/2021 | Buy Now | 48.08% | Citigroup | Joanna Wiensch | $141 → $154 | Maintains | Buy | Get Alert |
| 12/10/2021 | Buy Now | 40.38% | RBC Capital | Shagun Singh | — | Initiates | → Outperform | Get Alert |
| 10/27/2021 | Buy Now | 38.46% | Atlantic Equities | James Mainwaring | — | Upgrade | Neutral → Overweight | Get Alert |
| 10/21/2021 | Buy Now | 35.58% | Citigroup | Joanna Wiensch | $140 → $141 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Abbott Laboratories (ABT) stock?
The latest price target for Abbott Laboratories (NYSE:ABT) was reported by Evercore ISI Group on July 2, 2024. The analyst firm set a price target for $120.00 expecting ABT to rise to within 12 months (a possible 15.38% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abbott Laboratories (ABT)?
The latest analyst rating for Abbott Laboratories (NYSE:ABT) was provided by Evercore ISI Group, and Abbott Laboratories maintained their outperform rating.
When was the last upgrade for Abbott Laboratories (ABT)?
The last upgrade for Abbott Laboratories happened on July 21, 2023 when Wolfe Research raised their price target to N/A. Wolfe Research previously had an underperform for Abbott Laboratories.
When was the last downgrade for Abbott Laboratories (ABT)?
There is no last downgrade for Abbott Laboratories.
When is the next analyst rating going to be posted or updated for Abbott Laboratories (ABT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
Is the Analyst Rating Abbott Laboratories (ABT) correct?
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $125.00 to $120.00. The current price Abbott Laboratories (ABT) is trading at is $104.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.